Introduction. The use of hyaluronidase contributes to improvement in microcirculation, destruction of biofilms and reducing of congestion in patients with chronic prostatitis. Based on this mechanism, the use Longidaza® for the diagnosis of latent bacterial prostatitis was suggested.
Aim. To evaluate diagnostic and treatment capabilities of the long-acting enzyme preparation Longidaza® (rectal suppositories with an activity of 3000 IU), prescribed to patients with chronic prostatitis in routine clinical practice.
Materials and methods. A total of 39 men with chronic prostatitis of categories II and IIIa were included in open, prospective, non-interventional, comparative, single-center study. A microbiological study of expressed prostate secretion (EPS) was performed three times, at baseline, after using two suppositories Longidaza 3000 IU and after 7 weeks of therapy. From the 1st to the 10th suppository, Longidaza® was used every 48 hours, then, from the 11th to the 20th suppository, it was prescribed every 72 hours. The isolation of the pathogen was an indication for the antibiotic therapy. The treatment outcome was evaluated by using NIH-CPSI scale and laboratory and microbiological analysis of EPS.
Results. Diagnostic stage. Initially, pathogens were isolated in 27 (69.2%) patients. The number of leukocytes in EPS averaged 25.9±2.3. The use of two suppositories Longidaza® increased the number of patients with isolated pathogens to 33 (82%). In 7 out 12 patients with an initial diagnosis of abacterial prostatitis, the use of two suppositories of Longidaza® contributed to isolation of the pathogen in EPS (58.3%). The number of leukocytes in the EPS after enzymatic provocation increased by 50.2%. Treatment stage. The number of patients with isolated pathogens decreased from 33 to 7 (17.9%). The pain intensity decreased on average to 2.2±0.4 points, and in 27 (69.2%) men dysuria resolved. The quality of life significantly improved up to 1.3±0.2 points. The total score on NIH-CPSI scale decreased on average from 17.3±1.9 to 3.9±0.3 (p<0.05). An increased number of white blood cells in EPS was seen only in 5 (12.8%) men.
Conclusion. In many cases, bacterial prostatitis remains undiagnosed. Rectal suppositories Longidaza® can be recommended for the diagnosis of the latent bacterial chronic prostatitis, since this drug contributes to detection of pathogen and inflammation.

Keywords: bovhyaluronidase azoximer, androflor, latent chronic bacterial prostatitis, enzyme therapy, Longidaza®, chronic prostatitis, diagnosis, treatment